Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Inegy

Inegy is a new product that containes Simvastatin and Ezetimibe and it is licensed for hypercholesterolaemia.

The combination product would mean that a patient already taking the two separate products, or a patient who is not reaching target on a statin alone could be prescribed a single tablet that would have two cholesterol lowering effects.

However, the combination product cost approximately £8 per month more than the separate ingredients. This is equivalent to an additional 2 patients on treatment with the statin alone.

Action: At this time there can be no good reason to use this product over the separate ingredients, except perhaps for those patients with a known and significant compliance problem.

Share 'Inegy' on Email Share 'Inegy' on Delicious Share 'Inegy' on Digg Share 'Inegy' on Facebook Share 'Inegy' on Google+ Share 'Inegy' on reddit Share 'Inegy' on StumbleUpon Share 'Inegy' on Twitter

atomic-wealth

No Comments to “Inegy”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,523 spam comments.

atomic-wealth
fond-illness
summer